Acasti Pharma Inc. (NASDAQ:ACST) Q2 2023 Earnings Call Transcript

Shingrix was — during the period, Shingrix was launched, we analyzed the uptick curve of the lidocaine patches and they have grown at a healthy CAGR of 7%. So these non-PHN indications as well that we believe is a robust driver for GTX-101. So I’ll just pause here, if you have any further questions or Jan if you would like to add anything.

Jan D’Alvise: No, I thought that was a good summary for Prashant. Thank you. Sahil?

Sahil Kazmi: Yeah. No, that’s fantastic Prashant. Thank you so much for that additional color and for taking all of our questions. We look forward to seeing some of the data by the end of the year.

Jan D’Alvise: Yes. Thanks, Sahil. Really appreciate you being on the call today.

Sahil Kazmi: Absolutely. Thanks.

Operator: There are no more questions in the question queue. This concludes our question-and-answer session. I’d like to turn the conference back over to management for any closing remarks.

Jan D’Alvise: Okay. Thank you, Jason. Appreciate it. I want to thank everyone for taking the time to be with us today on the call. We’re really excited about the progress we’re making to deliver innovative new treatments to thousands of patients who currently lack effective therapies And we really look forward to updating you on our progress towards several key milestones coming in the next few months. So thanks again and I wish you all a great day. Take care.

Operator: Conference is now concluded. Thank you for attending today’s presentation. You may now disconnect.